LIPOSOMES: NEW APPROACHES FOR THE DELIVERY OF ANTIMICROBIAL DRUGS

Treating diseases is becoming more difficult. Antimicrobial resistance, infections that form biofilms, drugs that are unstable and toxicity that limits the dose all block treatment. Liposomes provide one solution. Liposomes are a spherical artificial vesicle made mainly from phospholipid bilayers that surround a watery core. Because of this design drugs that like water (hydrophilic) can stay inside the core while drugs that like fat (lipophilic) can sit inside the bilayer, which makes liposomes a flexible platform for delivering antimicrobials. This narrative review explains liposome structure, the ways of making liposomes the mechanisms that matter for antimicrobial delivery and how liposomes have been used against bacterial fungal, mycobacterial and biofilm-associated infections. Encapsulating a drug in a liposome can protect a drug from breaking down too early change where the drug goes in the body raise the drug concentration at the infection site and protect healthy tissue. Surface changes and stimulus-responsive designs may help liposomes interact better with tissue or biofilms. However how well a liposome works depends on the drug chemistry, the lipid composition, the vesicle size, the surface charge, the route of administration and the surrounding biological environment. Bringing these systems into use is slowed by complex manufacturing, limited storage stability, inconsistent drug release, scale-up challenges, cost and the need for stronger clinical evidence. Liposomes are therefore promising delivery systems. They do not automatically defeat antimicrobial resistance and each drug-pathogen pair must be evaluated on its own. Further work, on manufacturing, safety, pharmacokinetics and clinically meaningful outcomes is essential.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-12
DOI
https://doi.org/10.5281/zenodo.24155931
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

LIPOSOMES: NEW APPROACHES FOR THE DELIVERY OF ANTIMICROBIAL DRUGS

Janhavi Ranpura
Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
article

LIPOSOMES: NEW APPROACHES FOR THE DELIVERY OF ANTIMICROBIAL DRUGS

Janhavi Ranpura
article en

Abstract

Treating diseases is becoming more difficult. Antimicrobial resistance, infections that form biofilms, drugs that are unstable and toxicity that limits the dose all block treatment. Liposomes provide one solution. Liposomes are a spherical artificial vesicle made mainly from phospholipid bilayers that surround a watery core. Because of this design drugs that like water (hydrophilic) can stay inside the core while drugs that like fat (lipophilic) can sit inside the bilayer, which makes liposomes a flexible platform for delivering antimicrobials. This narrative review explains liposome structure, the ways of making liposomes the mechanisms that matter for antimicrobial delivery and how liposomes have been used against bacterial fungal, mycobacterial and biofilm-associated infections. Encapsulating a drug in a liposome can protect a drug from breaking down too early change where the drug goes in the body raise the drug concentration at the infection site and protect healthy tissue. Surface changes and stimulus-responsive designs may help liposomes interact better with tissue or biofilms. However how well a liposome works depends on the drug chemistry, the lipid composition, the vesicle size, the surface charge, the route of administration and the surrounding biological environment. Bringing these systems into use is slowed by complex manufacturing, limited storage stability, inconsistent drug release, scale-up challenges, cost and the need for stronger clinical evidence. Liposomes are therefore promising delivery systems. They do not automatically defeat antimicrobial resistance and each drug-pathogen pair must be evaluated on its own. Further work, on manufacturing, safety, pharmacokinetics and clinically meaningful outcomes is essential.

Zenodo (CERN European Organization for Nuclear Research)
Savitribai Phule Pune University (IN)
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon